Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Sage Therapeutics is a biopharmaceutical company focused on developing brain health medicines targeting CNS receptor systems, primarily GABA and NMDA. Its core product, ZURZUVAE, is an FDA-approved oral treatment for postpartum depression. The company advances novel compounds for neuropsychiatric and neurodevelopmental disorders, leveraging proprietary chemistry and strategic collaborations to develop and commercialize therapies that improve brain function and patient outcomes.
This description was generated via AI from an annual report. Updated about 1 year ago.